



## Roche partners with Cardihab on CVD

1 July 2023. Roche Diagnostics Australia Pty Ltd and [Cardihab Pty Ltd](#) are proud to announce a partnership that is focused on improving quality and standards of care, that deliver better outcomes for people living with cardiovascular conditions in Australia.

Roche sees this partnership as an integral part of their mission to deliver value-based health care along the entire patient journey, from diagnosis, through treatment and monitoring. An optimised care approach for people living with cardiovascular disease (CVD) has the potential to provide an improved care pathway that has been shown to reduce rates of hospital readmission, costs, and the burden of disease on patients quality of life.

Allison Rossiter, Managing Director of Roche Diagnostics Australia said that "We are committed to improving care access and outcomes for cardiac patients across Australia by leveraging our strengths and augmenting our offerings to deliver patient centric integrated solutions. We see Cardihab as a great organisation to collaborate with in realising this vision."

Cardihab CEO, Helen Souris says: "We are thrilled to partner with Roche, who share our passion for making a difference to the way care is delivered in Australia, and who value collaboration to drive change through innovative approaches. The complementary nature of Roche's diagnostic portfolio together with Cardihab's digital therapeutic solutions will accelerate our ability to realise our

purpose of providing patients with the care they need in ways that work for them.”

Cardiovascular disease refers to a class of conditions that affect the heart and blood vessels, including coronary heart disease, stroke and heart failure. Cardiovascular disease is one of the leading causes of death and disability in Australia. According to the Australian Bureau of Statistics, in 2019, CVD accounted for 25% of all deaths in the country<sup>1</sup>.

Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.

As part of the Roche Group, Roche Diagnostics Australia is a leading healthcare company that is committed to better outcomes for everyone in Australia.

CardiHab® is a digital therapeutic company that exists to help patients reach optimal health when at risk of, or living with, heart disease. Its scientifically validated Digital Cardiac Rehabilitation (DCR) solution uses smartphone apps and web portals to give healthcare providers the ability to deliver more convenient, flexible, and engaging cardiac rehabilitation services to patients.

For more information please visit [www.cardihab.com](http://www.cardihab.com)

Reference 1 - <https://www.aihw.gov.au/reports/heart-stroke-vascular-diseases/hsvd-facts/contents/about>